bioRxiv Science⌕ Search

Biology subjects

Watt, L.

Publications and source records attributed to Watt, L..

2 recordsLinked to original sources

Serotonin signaling modulates growth and motility in juvenile Fasciola hepatica

Fasciola hepatica causes fasciolosis, a parasitic disease that poses significant animal and human health challenges. Control relies on flukicides, most of which are adulticides, with only triclabendazole effective against the pathogenic migratory juvenile. Classical neurotransmitter pathways are widely targeted by anthelmintics yet remain underexplored for flukicide development. Here we explore the importance of serotonin (5-HT) signaling in juvenile fluke. In silico analyses confirmed all F. hepatica life stages express a complete 5-HT signaling pathway encompassing genes encoding proteins for 5-HT synthesis, transport, and reuptake, as well as five putative 5-HT G protein-coupled receptors (GPCRs). Homology and binding motif analyses supported the presence of two 5-HT1 (Fh5HT1A, Fh5HT1B) and three 5-HT7 (Fh5HT7A, -7B, -7C) GPCRs. Immunocytochemistry and in situ hybridization revealed widespread neuronal expression of 5-HT, its synthetic enzyme tryptophan hydroxylase (FhTPH), and the GPCR Fh5HT7C. 5-HT addition stimulated juvenile fluke motility; consistent with this observation, serotonin reuptake inhibition, which causes 5-HT persistence at synaptic junctions, also enhanced juvenile movement. Silencing of FhTPH, a key enzyme in 5-HT synthesis, blunted juvenile motility, a phenotype reversed by the addition of 5-HT. Silencing the fluke vesicular monoamine transporter (FhVMAT), which packages 5-HT into synaptic vesicles, reduced juvenile motility, whilst silencing the 5-HT reuptake transporter (FhSERT) which recycles synaptic 5-HT increased juvenile motility and growth, consistent with 5-HT accumulation enhancing effects. Whilst combinatorial silencing of Fh5HT1 receptors reduced fluke motility, silencing Fh5HT7 receptors led to a greater reduction in motility. Exogenous addition of 5-HT partially rescued motility deficits of juveniles with silenced Fh5HT1 receptors, but 5-HT excitation was abolished in Fh5HT7-RNAi juveniles, exposing their importance to fluke motility. Notably, sustained 5-HT exposure promoted juvenile growth, but these effects were not blunted by receptor-RNAi. The findings emphasize a central role of serotonin signaling in both juvenile motility and growth, exposing novel aspects of receptor function and encouraging therapeutic exploitation for liver fluke control. Author SummaryThe liver fluke, Fasciola hepatica, causes fasciolosis, a neglected tropical disease that poses a significant burden on human and animal health. There is no vaccine for fasciolosis and treatment relies on a single drug, triclabendazole, to control the early stages of infection which cause liver pathology whilst migrating through the mammalian host. Single drug reliance has increased the incidence of drug resistance in both human and animal populations, such that there is a pressing need for the characterization of novel drug targets and development of new anthelmintics targeting liver fluke. The focus of this research is to examine the role of the serotonin signaling system of liver fluke, bridging a gap in knowledge to enable the exploitation of this signaling pathway for flatworm drug development. Here, bioinformatic analysis has characterized the pathway components and receptors in multiple clinically relevant flatworm parasite species. Chemical and functional genomic methods have been used to prove the integral function of serotonin in liver fluke biology, regulating motility and growth, both essential for parasite infection and survival. This work provides data that help validate the serotonergic system of liver fluke as a potential target for future anthelmintic development.

molecular biology↗

Bisantrene potentiates tyrosine kinase inhibitor activity in clear cell renal cell carcinoma

Clear Cell Renal Cell Carcinoma (ccRCC) is the most prevalent kidney cancer and often develops resistance to standard therapies. This study aimed to assess if bisantrene, a multi-mechanistic agent with broad anticancer activity, can enhance the activity of standard of care ccRCC treatments. A panel of ccRCC cell lines were treated with bisantrene alone and in combination with common ccRCC drugs. Bisantrene showed moderate activity as a single agent, but strongly synergized with several ccRCC treatments, especially the tyrosine kinase inhibitors (TKIs) lenvatinib, pazopanib and cabozantinib. Cellular signaling pathways assessed by immunoblotting revealed the TKIs inhibit MET as well as downstream AKT and ERK signaling pathways as single agents. Combination of these TKIs with bisantrene was able to induce sustained downstream AKT inhibition and negate the rebound effect seen with TKI resistance. Overall, bisantrene shows promise as a new therapeutic agent for ccRCC in combination with TKIs.

cancer biology↗